Buthionine sulfoximine
- Generic Name
- Buthionine sulfoximine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H18N2O3S
- CAS Number
- 5072-26-4
- Unique Ingredient Identifier
- LW4108Q0BV
- Background
Buthionine sulfoximine has been used in trials studying the treatment of Neuroblastoma and Melanoma (Skin).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma
- Conditions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Duke University
- Registration Number
- NCT00661336
- Locations
- ๐บ๐ธ
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
๐บ๐ธM. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Chemotherapy in Treating Children With Neuroblastoma
- Conditions
- Locations
- ๐บ๐ธ
UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธChildren's Hospital Los Angeles, Los Angeles, California, United States
N99-02: Melphalan and Buthionine Sulfoximine
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-04-10
- Target Recruit Count
- 31
- Registration Number
- NCT00005835
- Locations
- ๐บ๐ธ
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States
๐บ๐ธChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
๐บ๐ธChildren's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.